1 January 2006   
News
Executive Vice President's Message
Tanzania Visit Illuminates Goals for CLSI Cooperative Agreement With CDC
Standards In Action: M2, M7, M100
CLSI Honor Roll and 2006 Awards Nominations
Press Releases
Standards Status
Vote and Deadlines
Recently Approved Documents
Call for Nominations
Events and Exhibits
Upcoming Events
Upcoming Presentations
CLSI Meetings Calendar
Participate in CLSI
Volunteer
New and Sustaining Members
Update Your Subscription
 
CLSI Home Page
Search Past Issues
Update Your Contact Information
Print this article Print all articles
 
 
 
Winner of the Silver Award for Patient Education in the WWW Health Awards Program

Recently Approved Documents
Performance Standards for Antimicrobial Disk Susceptibility Tests (M2-A9); Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically (M7-A7); Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement (M100-S16)

M2-A9Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard—Ninth Edition
Contains the current CLSI-recommended methods for disk susceptibility testing.
Purchase here.

M7-A7Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard—Seventh Edition
Describes standard broth dilution (macrodilution and microdilution) and agar dilution techniques for measuring the in vitro susceptibility of bacteria to antimicrobial agents.
Purchase here.

M100-S16Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement
Updated tables representing the most current information for drug selection, interpretation, and quality control using the procedures standardized in M2-A9 and M7-A7.    
Purchase here.
*Available for purchase only with M2-A9, M7-A7, or both.


Second Notice

M39-A2Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline—Second Edition 
Recommendations for consistent and effective use of cumulative susceptibility statistics, to enable clinicians to select the most appropriate agents for empiric antimicrobial therapy. 
Purchase here.


Our procedures have been designed to ensure that consensus has been achieved when a standard or guideline is published at the approved level. This means that a document has been rigorously reviewed by the authoring subcommittee, the area committee overseeing the project, the Board of Directors, and the medical-testing community that participates in the consensus process by carefully reviewing and commenting on the standard or guideline.

You may automatically receive or select approved-level documents as a member benefit.  Find out more about joining CLSI:  view membership options and benefits

  [ return to top ]

For more information or to contact us directly, please visit www.clsi.org
©2005 Clinical and Laboratory Standards Institute